CENBF has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CENBF has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, CEN Biotech's share price is $0.0002. CEN Biotech's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2023 was $0.02. Hence, CEN Biotech's PS Ratio for today is 0.01.
The historical rank and industry rank for CEN Biotech's PS Ratio or its related term are showing as below:
CEN Biotech's Revenue per Sharefor the three months ended in Mar. 2023 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2023 was $0.02.
The historical data trend for CEN Biotech's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CEN Biotech Annual Data | |||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | ||||||||||
PS Ratio | Get a 7-Day Free Trial | - | - | - | 14.00 | 2.74 |
CEN Biotech Quarterly Data | ||||||||||||||||||||
Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | |
PS Ratio | Get a 7-Day Free Trial | 3.58 | 2.33 | 3.46 | 2.74 | 1.18 |
For the Drug Manufacturers - Specialty & Generic subindustry, CEN Biotech's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, CEN Biotech's PS Ratio distribution charts can be found below:
* The bar in red indicates where CEN Biotech's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
CEN Biotech's PS Ratio for today is calculated as
PS Ratio | = | Share Price | / | Revenue per Share (TTM) |
= | 0.0002 | / | 0.017 | |
= | 0.01 |
CEN Biotech's Share Price of today is $0.0002.
CEN Biotech's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.02.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
PS Ratio | = | Market Cap | / | Revenue |
The Revenue here is for the trailing 12 months.
CEN Biotech (OTCPK:CENBF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.
Be Aware
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Thank you for viewing the detailed overview of CEN Biotech's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Lawrence Lehoux | director, officer: Chief Technology Officer | 11879 SOLOMAN ST, WINDSOR A6 N8P 1P1 |
Jeffery Allen Thomas | director | 23772 WEST ROAD #152, BROWNSTOWN TOWNSHIP MI 48183 |
Rick Leigh Purdy | director | 9 ELAINE STREET, ST. ALBERT A0 T8N7R6 |
Usamakh Saadikh | director | 3 DRUDBGY NARODOV SQUARE, KYIV 2H 04210 |
Joseph A. Byrne | director, officer: Chief Executive Officer | 6 CAMERON SIDE ROAD EAST, ESSEX A6 N8M 2X5 |
Alex Tarrabain | director | 18908 89 AVENUE, EDMONTON A0 T5T 6B7 |
Donald Strilchuck | director | 352 RIDEAU PL, TECUMSEH A6 N8N 3N9 |
Richard Boswell | director, 10 percent owner, officer: CFO Senior Executive VP | 2408 EASTERN AVE., ROCHESTER HILLS MI 48307 |
Ameen Ferris | director | 30 AYRSHIRE COURT, BRAMPTON A6 L6Z 0G6 |
Brian Payne | director, officer: Vice President | 1027 HUNTINGTON BLVD, BELLE RIVER A6 N0R 1A0 |
Aubrey De Lavenu Harold Andre | director | APT 627 VALE DO LOBO, ALMANCIL S1 8135-034 |
Bahige B. Chaaban | director, 10 percent owner, officer: Chief Executive Officer | 888 OLD TECUMSAH RD., BELLE RIVER A6 N0R 1A0 |
From GuruFocus
By ACCESSWIRE ACCESSWIRE • 11-08-2022
By ACCESSWIRE ACCESSWIRE • 07-13-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.